The new method makes antibiotic synthesis less long

BEIJING, Sept. 23 (Xinhua Zhang Mengran) The latest results of a drug study published in the British journal Nature on the 23rd, the U.S. team reported the successful completion of a modular synthesis of new antibiotics, this new antibiotic will hopefully avoid the problem of antibiotic resistance. Studies have shown that one of the compounds synthesized using this method is effective against drug-resistant strains in bacterial infection mouse models.
believe that new antibiotics are needed to stem the rise in drug-resistant infections. But only a very small number of new antibiotics have been developed in the past 30 years.
Antibiotics are essentially a class of secondary metabolites produced by microorganisms (including bacteria, fungi, line-out genus) or higher plants and animals in the course of life, with anti-pathogens or other active effects that interfere with the developmental function of other cells. However, drug resistance mechanisms appear in the course of collaborative evolution.
, for example, a family of antibiotics called streptococcus A is thought to be ineffective against strains that express Virginia mycomycin acetyl transferase (Vatase), which can invigorate the antibiotic. This time, a team of scientists at the University of California, San Francisco, reported a way to synthesize streptococcus A to avoid resistance caused by Vatase.
"starting from scratch" synthetic antibiotics in the lab is a long process because these complex molecules require multiple specially designed chain reactions. The research team adopted a modular approach to speeding up the process. They used a basic stent based on the naturally occurring streptococcus A, and then added interchangeable molecular building blocks (which bind to the cellular components of the bacteria, but are not easily combined with Vat) to produce a total of 62 streptococcus A similars. One of these compounds, Staphylococcus austratin resistant strains, has antibacterial activity and is effective in mouse models of bacterial infections. The team points out that their approach may extend the clinical life of streptococcus antibiotics.
In news and opinion papers published in the same time as the paper, Daniel Blair and Martin Booker, scientists at the University of Illinois at Urbana-Champaign, commented that the latest results will help develop streptococcus A, which avoids Vat-mediated resistance while maintaining potent antibacterial activity.